NCT02754141: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

NCT02754141
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT02754141

Comments are closed.

Up ↑